Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY ) revised its fourth-quarter revenue projection downward. Now estimating Q4 revenue at $13.5 billion, the company's projection falls short of analyst predictions of $13.96 billion.

Both missing market projections, Mounjaro is scheduled to bring in $3.5 billion while Zepbound is slated to generate $1.9 billion. Although the near future presented difficulties, Eli Lilly voiced hope for its long-term performance. The company expects income for fiscal 2025 between $58 billion and $61 billion, above the consensus among Wall Street of $58.52 billion. Advances in novel therapeutics and rising demand for its pharmaceutical portfolio help to define this growth trajectory.

Slower development in the U.S. incretin market and lower-than-expected inventory levels at year-end shaped the revised Q4 guidance. Lilly's emphasis on meeting growing demand with an expanding pipeline of therapies drives its ongoing positioning for future expansion.

This article first appeared on GuruFocus .